Table 2.

Baseline characteristics of patients stratified by race/ethnicity treated with PD at the time of initiation of PD

Variable	White	Black	Hispanic	Asian	Other
No. of subjects	10,123	4094	2263	713	598
Initial modality, %a
In-center HD	32	37	30	25	27
PD	68	63	70	75	73
Home HD	<1	<1	0	0	0
Interval from start of dialysis to treatment with modality, d	31 [9–165]	41 [11–214]	27 [9–137]	26 [9–136]	23 [6–128]
Age, yr	59±15	51±14	50±16	55±16	54±15
Men, %	60	48	56	53	57
Primary health insurance, %
Medicare	49	42	45	38	43
Medicaid	3	4	11	7	6
Initially uninsured	3	4	5	4	4
Veterans Affairs	1	1	<1	<1	<1
Otherb	44	50	39	51	47
Cause of ESRD, %
Diabetes	39	36	50	35	49
Hypertension	24	38	22	28	24
Glomerular disease	16	16	14	23	15
Other	21	10	13	14	12
H/o previous transplant, %	3	2	2	3	2
Comorbidities, %
Diabetes	61	63	70	60	68
Hypertension	51	63	47	51	46
Congestive heart failure	19	23	18	14	18
Atherosclerotic heart disease	19	14	13	14	16
Other cardiovascular	17	13	12	9	14
Dyslipidemia	48	43	44	51	42
Baseline body mass index, kg/m2	28±6	29±7	27±6	24±4	28±6
Laboratory variables from first 91-d period of treatment with PD
Hemoglobin, g/dl	11.6±1.3	11.2±1.4	11.4±1.3	11.5±1.3	11.4±1.4
Iron saturation, %	27 [21–35]	28 [22–35]	28 [22–36]	30 [24–40]	27 [21–35]
Serum ferritin, ng/ml	286 [146–536]	327 [165–612]	273 [136–530]	353 [183–637]	294 [142–581]
Serum albumin, g/dl	3.7±0.5	3.6±0.5	3.6±0.5	3.7±0.5	3.7±0.5
Weekly total Kt/V	2.5±0.8	2.4±0.8	2.5±0.8	2.6±0.8	2.6±0.8
Residual renal Kt/V	1.1±0.8	0.9±0.8	0.9±0.8	1.0±0.8	1.0±0.8
Serum calcium, mg/dl	8.9±0.6	8.7±0.7	8.6±0.7	8.8±0.7	8.7±0.7
Serum phosphorous, mg/dl	5.0±1.3	5.0±1.3	5.2±1.3	5.1±1.2	5.0±1.2
Parathyroid hormone, pg/ml	251 [152–397]	414 [260–665]	335 [220–511]	284 [173–458]	290 [194–456]
Alkaline phosphatase, IU/L	80 [64–104]	82 [65–107]	89 [70–115]	74 [59–96]	80 [65–105]
Hemoglobin A1C, %	6.8 [6.0–7.7]	6.8 [5.9–7.8]	6.9 [6.1–7.9]	6.6 [5.9–7.6]	6.8 [6.1–8.1]
Potassium, mEq/L	4.2±0.5	4.1±0.5	4.3±0.6	4.3±0.6	4.2±0.5
Bicarbonate, mEq/L	25±3	25±3	24±3	24±3	24±3
4-h D/P creatinine ratio	0.65±0.12	0.65±0.12	0.65±0.13	0.64±0.13	0.66±0.11
iv Medication from first 91-d period of treatment with PD
Cumulative iron, mg/mo	0 [0–325]	0 [0–300]	100 [0–400]	0 [0–300]	0 [0–350]
ESA median week dose, units	4992 [1650–11,971]	5648 [1886–13,514]	5067 [1703–11,622]	4840 [1400–11,000]	4950 [1800–11,000]
PD modality, %
Initial treatment with APD	58	58	60	58	47
Ever treated with APD	86	86	88	84	84
Geographic location, %
Northeast	13	11	6	8	7
Midwest	25	16	6	9	10
West	20	10	48	60	48
South	42	63	40	23	36
Year of incidence, %
2007	19	21	19	22	19
2008	20	20	19	19	22
2009	22	21	21	21	21
2010	23	23	23	22	21
2011	16	15	17	17	16

Data are presented as means±SDs, medians [interquartile ranges], or proportions where appropriate. H/o, history of; D/P, 4-hour dialysate to plasma ratio; ESA, eryhtropoiesis stimulating agents; APD, auotmoated peritoneal dialysis.

^aOf patients with an assigned modality during the first 91-day period of dialysis (n=15,706).

^bIncludes Medicare Advantage plans, managed care Medicaid, and employer–based health insurance.